Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aim Immunotech Inc (AIM)

2.09   -0.17 (-7.52%) 03-05 07:27
Open: 2.23 Pre. Close: 2.26
High: 2.2501 Low: 2
Volume: 2,305,613 Market Cap: 85M
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. The company is headquartered in Ocala, Florida and currently employs 31 full-time employees. The firm is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The firm's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The firm's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.252 - 2.271 2.271 - 2.283
Low: 1.965 - 1.984 1.984 - 1.996
Close: 2.065 - 2.095 2.095 - 2.114

Technical analysis

as of: 2021-03-04 5:04:22 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.07     One year: 3.57
Support: Support1: 1.94    Support2: 1.61
Resistance: Resistance1: 2.63    Resistance2: 3.06
Pivot: 2.44
Moving Average: MA(5): 2.26     MA(20): 2.49
MA(100): 2.10     MA(250): 2.33
MACD: MACD(12,26):     Signal(9): 0.06
Stochastic oscillator: %K(14,3): 17.66     %D(3): 21.46
RSI: RSI(14): 40.27
52-week: High: 7.11  Low: 1.60  Change(%): -0.5
Average Vol(K): 3-Month: 391062  10-Days: 207618

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AIM has closed above bottom band by 6.5%. Bollinger Bands are 63.7% wider than normal. The large width of the bands suggest high volatility as compared to AIM's normal range. The bands have been in this wide range for 19 bars. This is a sign that the current trend might continue.

Headline News

Thu, 04 Mar 2021
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th - Yahoo Finance

Wed, 24 Feb 2021
AIM ImmunoTech Inc (AIM) Stock Has Fallen -5.20% This Week: Buy, Hold, or Sell? - InvestorsObserver

Wed, 24 Feb 2021
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer - Yahoo Finance

Tue, 16 Feb 2021
AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy - Yahoo Finance

Wed, 10 Feb 2021
AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands - Yahoo Finance

Wed, 10 Feb 2021
Is AIM ImmunoTech Inc (AIM) The Right Choice in Biotechnology? - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 40
Shares Float (M) 39
% Held by Insiders 2.00
% Held by Institutions 2.10
Shares Short (K) 1,920
Shares Short P. Month (K) 2,690

Stock Financials

EPS -5.873
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.140
Profit Margin
Operating Margin -6562.25
Return on Assets (ttm) -25.1
Return on Equity (ttm) -42.2
Qtrly Rev. Growth 37.9
Gross Profit (p.s.) -0.019
Sales Per Share 0.005
EBITDA (p.s.) -0.304
Qtrly Earnings Growth
Operating Cash Flow (M) -9
Levered Free Cash Flow (M) -7

Stock Valuations

PE Ratio -0.36
PEG Ratio
Price to Book value 0.98
Price to Sales 423.22
Price to Cash Flow -8.86

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.